Sugammadex Clinical Trial Issues Still Causing Trouble For Merck
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After FDA abruptly cancelled an advisory committee meeting on the anesthesia injection product in July to review trial site inspection results for a hypersensitivity study, it issues a “complete response” letter indicating site “operational” concerns.